State-of-the art pharmacotherapy for non-neovascular age-related macular degeneration

References

• Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697–704.
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Bougatsos C, et al. Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2016;315:915–933.
   PubMed Web of Science ®Google Scholar
• Al-zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017;12:1313–1330.
   PubMed Web of Science ®Google Scholar
• Davis MD, Gangnon RE, Lee LY, et al. The age-related eye disease study severity scale for age-related macular degeneration: AREDS report No. 17. Arch Ophthalmol. 2005;123:1484–1498.
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica. 2012;227:11–20.
   PubMed Web of Science ®Google Scholar
• Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353–363.
   PubMed Web of Science ®Google Scholar
• Rikans LE, Moore DR. Effect of aging on aqueous-phase antioxidants in tissues of male Fischer rats. Biochim Biophys Acta. 1988;966:269–275.
   PubMedGoogle Scholar
• Vandewoude MFJ, Vandewoude MG. Vitamin E status in a normal population: the influence of age. J Am Coll Nutr. 1987;6:307–311.
   PubMed Web of Science ®Google Scholar
• Castorina C, Campisi A, Di Giacomo C. Lipid peroxidation and antioxidant enzymatic systems in rat retina as a function of age. Neurochem Res. 1992;17:599–604.
   PubMed Web of Science ®Google Scholar
• Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115–134.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jang YP, Kim SR, et al. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA. 2006;103:16182–16187.
   PubMed Web of Science ®Google Scholar
• Gabai A, Veritti D, Lanzetta P. Fundus autofluorescence applications in retinal imaging. Indian J Ophthalmol. 2015;63:406–415.
   PubMed Web of Science ®Google Scholar
• Michalska-Małeckaa K, Kabiesza A, Nowak M, et al. Age related macular degeneration – challenge for future: pathogenesis and new perspectives for the treatment. Eur Geriatric Med. 2015;6:69–75.
   Web of Science ®Google Scholar
• Anderson DH, Mullins RF, Hageman GS, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411–431.
   PubMed Web of Science ®Google Scholar
• Farazdaghi MK, Ebrahimi KB. Role of the choroid in age-related macular degeneration: a current review. J Ophthalmic Vis Res. 2019;14:78–87.
   PubMed Web of Science ®Google Scholar
• Ramrattan RS, van der Schaft TL, Mooy CM, et al. Morphometric analysis of Bruch’s membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857–2864.
   PubMed Web of Science ®Google Scholar
• Pauleikhoff D, Harper CA, Marshall J. Aging changes in Bruch’s membrane. A histochemical and morphologic study. Ophthalmology. 1990;97:171–178.
   PubMed Web of Science ®Google Scholar
• Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296:301–309.
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Hankinson SE, Guo Q, et al. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol. 2007;125:55–62.
   PubMed Web of Science ®Google Scholar
• Francis PJ, Zhang H, Dewan A, et al. Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population. Mol Vis. 2008;14:1395–1400.
   PubMed Web of Science ®Google Scholar
• Kaur I, Katta S, Hussain A, et al. Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients. Invest Ophthalmol Vis Sci. 2008;49:1771–1776.
   PubMed Web of Science ®Google Scholar
• Baird PN, Guida E, Chu DT, et al. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:1311–1315.
   PubMed Web of Science ®Google Scholar
• Neuner B, Wellmann J, Dasch B, et al. Modeling smoking history: a comparison of different approaches in the MARS study on age-related maculopathy. Ann Epidemiol. 2007;17:615–621.
   PubMed Web of Science ®Google Scholar
• Delcourt C, Diaz J, Ponton-Sanchez A. Smoking and age-related macular degeneration. Arch Ophthalmol. 1998;116:1031–1035.
   PubMedGoogle Scholar
• Wang JJ, Ross RJ, Tuo J, et al. The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study. Ophthalmology. 2008;115:693–699.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Rochtchina E, Smith W, et al. Combined effects of complement factor H genotypes, fish consumption, and inflammatory markers on long-term risk for age-related macular degeneration in a cohort. Am J Epidemiol. 2009;169:633–641.
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Lee KE, et al. Measures of obesity and age-related eye diseases. Ophthalmic Epidemiol. 2001;8:251–262.
   PubMedGoogle Scholar
• Chong EW, Kreis AJ, Wong TY, et al. Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol. 2008;145:707–715.
   PubMed Web of Science ®Google Scholar
• Johnson LV, Leitner WP, Rivest AJ, et al. The Alzheimer’s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:11830–11835.
   PubMed Web of Science ®Google Scholar
• Chew EY, Clemons TE, Agrón E, et al. Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013;120:1604–1611.
   PubMed Web of Science ®Google Scholar
• Kolar P. Classification and clinical features of AMD. Age-related macular degeneration - etiology, diagnosis and management - a glance at the future. London: Intech; 2013.
   Google Scholar
• Sarks SH, Council Lecture. Drusen and their relationship to senile macular degeneration. Aust J Ophthalmol. 1980;8:117–130.
   PubMedGoogle Scholar
• Fine SL, Berger JW, Maguire MG, et al. Age related macular degeneration. N Engl J Med. 2000;342:483–492.
   PubMed Web of Science ®Google Scholar
• Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM epidemiological study group. Surv Ophthalmol. 1995;39:367–374.
   PubMed Web of Science ®Google Scholar
• Seddon JM, Sharma S, Adelman RA. Evaluation of the clinical age-related maculopathy staging system. Ophthalmology. 2006;113:260–266.
   PubMed Web of Science ®Google Scholar
• Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS report No. 18. Arch Ophthalmol. 2005;123:1570–1574.
   PubMed Web of Science ®Google Scholar
• Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001;42:2237–2241.
   PubMed Web of Science ®Google Scholar
• Van Leeuwen R, Klaver CC, Vingerling JR, et al. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003;121:519–526.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the blue mountains eye study. Ophthalmology. 2007;114:92–98.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumu- lative incidence of age-related macular degeneration: the Bea- ver Dam eye study. Ophthalmology. 2007;114:253–262.
   PubMed Web of Science ®Google Scholar
• Lanzetta P, Mitchell P, Wolf S, et al. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. Br J Ophthalmol. 2013;97:1497–1507.
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Missiroli F, et al. Twelve-month outcomes of intravitreal aflibercept for neovascular age-related macular degeneration: fixed versus as-needed dosing. Retina. 2019;39:2077–2083.
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Parravano M, et al. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. Eur J Ophthalmol. 2017;27:74–79.
   PubMed Web of Science ®Google Scholar
• Gorusupudi A, Nelson K, Bernstein PS. The age-related eye disease 2 study: micronutrients in the treatment of macular degeneration. American society for nutrition. Adv Nutr. 2017;8:40–53.
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. AREDS report no. 8. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol. 2001;119:1417–1436.
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005–2015.
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study 2 Research Group. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132:142–149.
   PubMed Web of Science ®Google Scholar
• Georgiou T, Prokopiou E. The new era of omega-3 fatty acids supplementation: therapeutic effects on dry age-related macular degeneration. J Stem Cells. 2015;10:205-215.
   PubMedGoogle Scholar
• Souied EH, Delcourt C, Querques G, et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration. Ophthalmology. 2013;120:1619–1631.
   PubMed Web of Science ®Google Scholar
• Querques G, Souied EH. The role of omega-3 and micronutrients in age-related macular degeneration. Surv Ophthalmol. 2014;59:532–539.
   PubMed Web of Science ®Google Scholar
• Aoki A, Inoue M, Nguyen E, et al. Dietary n-3 fatty acid, α-tocopherol, zinc, vitamin D, vitamin C and β-carotene are associated with age-related macular degeneration in Japan. Sci Rep. 2016;6:20723.
   PubMed Web of Science ®Google Scholar
• Seddon JM, George S, Rosner B. Cigarette Smoking, Fish Consumption, Omega-3 Fatty Acid Intake, and Associations With Age-Related Macular Degeneration. Arch Ophthalmol. 2006;124:995.
   PubMed Web of Science ®Google Scholar
• Chua B, Flood V, Rochtchina E, et al. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol. 2006;124:981–986.
   PubMedGoogle Scholar
• Georgiou T, Neokleous A, Nicolaou D, et al. Pilot study for treating dry age-related macular degeneration (AMD) with high-dose omega-3 fatty acids. PharmaNutrition. 2014;2:8–11.
   Google Scholar
• Querques G, Merle BMJ, Pumariega NM, et al. Dynamic drusen remodelling in participants of the nutritional AMD treatment-2 (NAT-2) randomized trial. PLoS One. 2016;11:e0149219.
   PubMed Web of Science ®Google Scholar
• Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2015;4:CD010015.
   Google Scholar
• Souied EH, Aslam T, Garcia-Layana A, et al. Omega-3 fatty acids and age-related macular degeneration. Ophthalmic Res. 2015;55:62–69.
   PubMed Web of Science ®Google Scholar
• Do DV, Pieramici DJ, Van Lookeren Campagne M, et al. A phase Ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina. 2014;34:313–320.
   PubMed Web of Science ®Google Scholar
• Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med. 2017;9:1443.
   Web of Science ®Google Scholar
• Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration. JAMA Ophthalmol. 2018;136:666.
   PubMed Web of Science ®Google Scholar
• Blumenkranz MS, Leung L-S, Martin DF, et al. Pharmacotherapy of age-related macular degeneration. In: Ryan SJ, editor. Retina. 5th ed. PA: Saunders; 2013. p. 1213–1255.
   Google Scholar
• Kassa E, Ciulla TA, Hussain RM, et al. Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019;19:335–342.
   PubMed Web of Science ®Google Scholar
• Aharoni R. Immunomodulation neuroprotection and remyelination – the fundamental therapeutic effects of glatiramer acetate: A critical review. J Autoimmun. 2014;54:81–92.
   PubMed Web of Science ®Google Scholar
• Landa G, Butovsky O, Shoshani J, et al. Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res. 2008;33:1011–1013.
   PubMed Web of Science ®Google Scholar
• Zarling JA, Brunt VE, Vallerga AK, et al. Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015;6:325.
   PubMed Web of Science ®Google Scholar
• Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Opthalmol Vis Sci. 2010;51:6131.
   PubMed Web of Science ®Google Scholar
• Nebbioso M, Lambiase A, Cerini A, et al. Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules. Int J Mol Sci. 2019;20:1693.
   Web of Science ®Google Scholar
• Jaffe GJ, Kaiser PK, Kuppermann BD, et al. Primary results from phase 2 study of risuteganib in intermediate dry AMD. Presented at: The American Academy of Ophthalmology (AAO) 2019 Annual Meeting; October 12–15, 2019; San Francisco, California. Abstract PO435.
   Google Scholar
• Chen M, Liu B, Ma J, et al. Protective effect of mitochondria-targeted peptide MTP-131 against oxidative stress-induced apoptosis in RGC-5 cells. Mol Med Rep. 2017;15:2179–2185.
   PubMed Web of Science ®Google Scholar
• Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary®, an extended-release capsule formulation of carbidopa–levodopa. Clin Pharmacokinet. 2017;56:999–1014.
   PubMed Web of Science ®Google Scholar
• Falk T, Congrove NR, Zhang S, et al. PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel microcarriers. J Biomed Biotechnol. 2012;2012:1–8.
   PubMedGoogle Scholar
• Brilliant MH, Vaziri K, Connor TB, et al. Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration. Am J Med. 2016;129:292–298.
   PubMed Web of Science ®Google Scholar
• Radu RA, Han Y, Bui TV, et al. Reductions in serum Vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Opthalmol Vis Sci. 2005;46:4393.
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013;33:498–507.
   PubMed Web of Science ®Google Scholar
• Saad L, Washington I. Can Vitamin A be improved to prevent blindness due to age-related macular degeneration, stargardt disease and other retinal dystrophies? Adv Exp Med Biol. 2016;854:355–361.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Ruitenberg M, Freitag CE, et al. MRZ-99030 – A novel modulator of Aβ aggregation: I – mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer’s disease, glaucoma and age-related macular degeneration (AMD). Neuropharmacology. 2015;92:158–169.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Ruitenberg M, Freitag CE, et al. MRZ-99030 – A novel modulator of Aβ aggregation: I – mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer’s disease, glaucoma and age-related macular degeneration (AMD). Neuropharmacology. 2015;92:158–169.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Berger B, Reichel E, et al. A randomized phase 2 study of an anti–amyloid β monoclonal antibody in geographic atrophy secondary to age-related macular degeneration. Ophthalmol Retin. 2018;2:1028–1040.
   PubMedGoogle Scholar
• Augustin AJ, Diehm C, Grieger F, et al. Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial. Expert Opin Investig Drugs. 2013;22:803–812.
   PubMed Web of Science ®Google Scholar
• Resch H, Weigert G, Karl K, et al. Effect of systemic moxaverine on ocular blood flow in humans. Acta Ophthalmol. 2009;87:731–735.
   PubMed Web of Science ®Google Scholar
• Pemp B, Garhofer G, Lasta M, et al. The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects. Acta Ophthalmol. 2012;90:139–145.
   PubMed Web of Science ®Google Scholar
• Shiragami C, Miyake M, Fujiwara A, et al. Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration. Medicine (Baltimore). 2017;96:6422.
   PubMed Web of Science ®Google Scholar
• Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent. Arch Ophthalmol. 2009;127:402.
   PubMed Web of Science ®Google Scholar
• Nizari S, Guo L, Davis BM, et al. Non-amyloidogenic effects of α2 adrenergic agonists: implications for brimonidine-mediated neuroprotection. Cell Death Dis. 2016;7:2514.
   PubMed Web of Science ®Google Scholar
• Freeman WR Intravitreal brimonidine drug delivery system (brimonidine DDS) in patients with geographic atrophy: A phase 2 study. Presented at: American Academy of Ophthalmology (AAO) 2016 Annual Meeting; October 14–18, 2016; Chicago, Illinois.
   Google Scholar
• Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Opthalmol Vis Sci. 2012;53:7484.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci. 2011;108:6241–6245.
   PubMed Web of Science ®Google Scholar
• Vugler A, Carr A-J, Lawrence J, et al. Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, expansion and retinal transplantation. Exp Neurol. 2008;214:347–361.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–516.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379:713–720.
   PubMed Web of Science ®Google Scholar
• McGill TJ, Cottam B, Lu B, et al. Transplantation of human central nervous system stem cells - neuroprotection in retinal degeneration. Eur J Neurosci. 2012;35:468–477.
   PubMed Web of Science ®Google Scholar
• Cashman SM, Ramo K, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS ONE. 2011;6:19078.
   PubMed Web of Science ®Google Scholar
• Veritti D, Macor S, Menchini F, et al. Effects of VEGF inhibition on retinal morphology, neovascular network size, and visual acuity in patients with vascularized pigment epithelium detachment because of occult choroidal neovascularization. Retina. 2013;33:982–989.
   PubMed Web of Science ®Google Scholar
• Sarao V, Parravano M, Veritti D, et al. Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina. 2016;36:770–777.
   PubMed Web of Science ®Google Scholar
• Santarelli M, Diplotti L, Samassa F, et al. Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opin Pharmacother. 2015;16:1769–1781.
   PubMed Web of Science ®Google Scholar
• Gabai A, Veritti D, Lanzetta P. One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting. Eur J Ophthalmol. 2014;24:396–401.
   PubMed Web of Science ®Google Scholar